NCT01821911View on ClinicalTrials.gov

The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

PHASE4CompletedINTERVENTIONAL
Enrollment

10,500

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions
Rabies Vaccine AllergyVaccination Adverse EventAnti-D Antibodies
Interventions
BIOLOGICAL

Zagreb2-1-1

Injection on day 0、7、21

BIOLOGICAL

Essen

Injection on day 0、3、7、14、28

Trial Locations (3)

Unknown

Guangdong Centers for Disease Control and Prevention, Zhaoqing

Wuhan Centers for Disease Control and Prevention, Wuhan

Beijing Chaoyang District Centers for Disease Control and Prevention, Beijing

All Listed Sponsors
lead

Beijing Center for Disease Control and Prevention

OTHER_GOV

NCT01821911 - The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use | Biotech Hunter | Biotech Hunter